Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has shared an update.
Shanghai Henlius Biotech, Inc. has announced an extraordinary general meeting to be held on July 21, 2025, to consider and approve several resolutions related to its Share Option Scheme and RSU Scheme. These resolutions include authorizing the issuance of shares and granting RSUs, which could impact the company’s operational flexibility and stakeholder interests.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development and commercialization of monoclonal antibody drugs. The company operates in the pharmaceutical industry, targeting markets with high demand for innovative cancer treatments and other therapeutic areas.
Average Trading Volume: 1,411,759
Technical Sentiment Signal: Buy
Current Market Cap: HK$28.7B
See more data about 2696 stock on TipRanks’ Stock Analysis page.